Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin and Pembrolizumab in Soft Tissue Sarcomas
NCT03899805Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2019
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of eribulin and pembrolizumab in Liposarcoma, leiomyosarcoma (LMS) and undifferentiated pleomorphic sarcoma (UPS) (3 cohorts), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Progression-Free Survival at 12 weeks. Started Jun 2019; status: completed.
02
Drugs
eribulinpembrolizumab
03
Conditions
Liposarcomaleiomyosarcoma (LMS)undifferentiated pleomorphic sarcoma (UPS)
Beyond the preview
Go deeper on NCT03899805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899805.